Racial and Ethnic Disparities and Health Inequities in Lung Cancer

This activity is part of a series


Ana I. Velázquez Mañana, MD, MSc
Assistant Professor, Division of Hematology Oncology, Zuckerberg San Francisco General Hospital
Assistant Director of Diversity, Equity, Inclusion and Accessibility, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Ana I. Velázquez Mañana, MD, MSc

Dr. Ana Velázquez Mañana is a thoracic oncologist and Assistant Professor of Medicine in the University of California, San Francisco (UCSF) Division of Hematology/Oncology at Zuckerberg San Francisco General Hospital in California. As a Latina, she advocates for workforce diversity and gender equity and has been named the Assistant Director of Diversity, Equity, Inclusion, and Accessibility for Training of the Helen Diller Family Comprehensive Cancer Center at UCSF. Dr. Velázquez completed her MD at the University of Puerto Rico School of Medicine, a Master of Biomedical Science at Mayo Clinic Graduate School of Biomedical Sciences (formerly known as Mayo Graduate School), and her Internal Medicine residency at Mount Sinai Beth Israel, where she was a Chief Resident. She joined UCSF in 2018, where she completed her clinical fellowship in Medical Oncology and postdoctoral research fellowship in the National Clinician Scholars Program.

Dr. Velázquez is a member of the prestigious John A. Watson Faculty Scholars Class of 2022 at UCSF and has been awarded a Conquer Cancer Foundation Young Investigator Award. She aims to support and improve the outcomes of patients with lung cancer from vulnerable backgrounds using health services and disparities research.

Gilberto de Lima Lopes Junior, MD, MBA, FASCO
Professor of Clinical Medicine, Interim Chief, Division of Medical Oncology, Miller School of Medicine, Medical Director for International Programs, Associate Director for Global Oncology, Sylvester Comprehensive Cancer, University of Miami Health Systems, Miami, FL
Gilberto de Lima Lopes Junior, MD, MBA, FASCO

Gilberto Lopes is Medical Director for International Programs and Associate Director for Global Oncology at the Sylvester Comprehensive Cancer Center as well as Chief of the Medical Oncology Division and Professor of Clinical Medicine at the University of Miami Miller School of Medicine. He currently serves on the Board of Directors for the Union for International Cancer Control and as Editor-in-Chief for the American Society of Clinical Oncology’s journal, JCO Global Oncology. He completed medical school at the Federal University of Rio Grande do Sul in Brazil and residency in internal medicine, chief residency, and hematology and medical oncology fellowship at the University of Miami and Jackson Memorial Hospital. Dr. Lopes served as Assistant Professor of Oncology at the Johns Hopkins University, Senior Consultant and Associate Director for Clinical Research at the Johns Hopkins Singapore International Medical Center, and Chief Medical and Scientific Officer for Grupo Oncoclínicas, the largest oncology provider in Latin America and one of the largest in the world.

Dr. Lopes has published more than 200 papers and book chapters, with articles featured in journals such as the Journal of Clinical Oncology, Cancer, Nature Reviews, Lancet, Lancet Oncology, and Health Affairs. In addition to delivering lectures around the world, he has been principal, co-principal investigator, or steering committee member in more than 150 studies and clinical trials covering breast, gastrointestinal, genitourinary, and thoracic cancers. His other main areas of research interest are disparities, health economics, value, policy, and access to cancer drugs and care in low- and middle-income countries.

Statement of Need

Every two and a half minutes, someone receives a diagnosis of lung cancer in the United States. Each day, nearly 400 people succumb to lung cancer. While the survival rate for lung cancer—the leading cause of cancer mortality—has markedly increased over the past 5 years, gaps in early diagnosis, treatment options and access, survival rate, and more remain for underserved populations, including those of varying racial and ethnic groups. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncological treatment for lung cancer, thus resulting in delayed diagnosis, clinical management and treatment, prognosis, and survival rate.

In this CME Outfitters podcast, expert faculty will review recent data and discuss the impact of biases, disparities, and health inequities that reduce the quality of oncology care for underserved racial and ethnic underserved patients with lung cancer. This program will set the stage for intervention, empowering attendees to recognize and consider factors to improve lung cancer treatment.

Learning Objectives

At the end of this CME/CE activity, participants should be able to understand and acknowledge the influence of bias, disparities, and inequities on lung cancer care.

Financial Support

Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.

Target Audience

Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, dietitians, and case managers specializing in oncology, pathology, radiology, pulmonology, and/or primary care

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.75

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.75

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.75

This application-based activity is approved for 0.75 contact hour (0.075 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-22-122-H01-P

Physician Assistants (AAPA): 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

Dietetics (CDR)

Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU). If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60 minute hour = 1 CPEU). RDs and DTRs are to select activity type 102 in their Activity Log. Performance indicator selection is at the learner’s discretion.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Velázquez Mañana reports the following financial relationships:

  • Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc.
  • Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology

Dr. Lopes reports the following financial relationships:

  • Consultant: Amgen Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
  • Research Support: Abbvie Inc.; Adaptimmune Therapeutics plc.; AstraZeneca; Bavarian Nordic; Blueprint Medicines Corporation; Bristol Myers Squibb Company; EMD Serono, Inc.; E.R. Squibb & Sons, LLC; G1 Therapeutics, Inc.; Genentech, Inc.; GSK; Janssen Pharmaceuticals, Inc.; Lilly; Lucence Diagnostics; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Rgenix, Inc.; Roche; Tesaro, Inc.; and Xilis, Inc.
  • Stock Options: Lucence Diagnostics and Xilis, Inc.
  • Travel, Accommodations, or Expenses: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; E.R. Squibb & Sons, LLC; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Pfizer Inc.; Pharmacyclics, Inc.; Seagen Inc.; and Seattle Genetics, Inc.
  • Other Material or Financial Support: Mirati Therapeutics, Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Jeffrey Helfand, DO (peer reviewer)
  • Meghann Taft-Lockhard (planning committee)
  • Kashemi D. Rorie, PhD (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.


Racial and Ethnic Disparities and Health Inequities in Lung Cancer
Event Date: 10/12/2022 at 4:00 am EST